Risk factors
Gain Therapeutics (GANX) risk factors
Item 1A of every Gain Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
57 risks, 8 new, 3 dropped, 6 reworded since the prior year. Gain Therapeutics added significant risk disclosures regarding US government shutdowns impacting the SEC and FDA, international tariffs, and the newly enacted BIOSECURE Act impacting its reliance on Chinese partners such as WuXi AppTec.
Filed Mar 26, 2026 - FY2024 10-K risk factors
52 risks. Gain Therapeutics faces high regulatory hurdles for its novel Magellan platform and Parkinson's drug candidates. Heavy reliance on Chinese supplier WuXi AppTec creates geopolitical supply chain risks. Protection of intellectual property and third-party clinical trial dependence are critical.
Filed Mar 27, 2025